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Abstract
Background: Patients often present with facial pain ascribed to sinusitis, despite normal nasal endoscopy and sinus
computed tomography. Facial pain is increasingly recognised to be of neurological origin.
Method: A cohort of 240 patients with chronic facial pain was followed up for 36 months at an otolaryngological
practice in Malta. The types of facial pain were classified according to International Headache Classification criteria.
The body mass index, occupation and educational level of patients were compared with the general population.
Results: Tension-type mid-facial pain and facial migraine without aura were the most common types of chronic
facial pain. The sites of pain, symptoms, treatment and outcomes for these principal pain types are discussed.
Patients with mid-facial pain were treated with low-dose amitriptyline for eight weeks. After three years, nearly
half of the patients were symptom free, and in a third the pain changed from being chronic to being episodic. The
treatment of patients with facial migraine was more varied but the length of time until recurrence of pain was similar.
Conclusion: The most effective long-term treatments for tension-type mid-facial pain and facial migraine were
low-dose amitriptyline and low-dose amitriptyline and triptans, respectively.
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Introduction
The study was set in a community-based otolaryngol-
ogy practice in Malta. Retrospective records of 7476
patients presenting at a rhinology clinic showed that
25 per cent had significant facial pain. A cohort of
240 patients who satisfied the criteria for chronic
facial pain was followed for 3 years in an attempt to
classify the types of facial pain according to
International Headache Society criteria1 and to report
on long-term patient outcome. The study aimed to iden-
tify clinical patterns in these patients that could help the
otolaryngologist distinguish between the main categor-
ies of chronic facial pain. The body mass index (BMI),
occupation and educational level of this cohort were
compared to those in the general population.
A recent study of 305 Maltese patients who satisfied
the 1997 American Academy Taskforce clinical criteria
for chronic rhinosinusitis identified facial pain as the
commonest principal presenting symptom. However,
60 per cent of these patients had normal sinus com-
puted tomography (CT) scans.2 ‘Sinusitis’ may there-
fore not have been an appropriate diagnosis in spite
of chronic facial pain.3 The European Position Paper
of 2007 published revised diagnostic criteria for rhino-
sinusitis that included correlation of CT with nasal
endoscopic findings.4 The 2012 update contained a
section on facial pain as this may present under the
guise of chronic rhinosinusitis.5
Patients presenting with symptoms of rhinosinusitis,
but with normal sinus CT and nasal endoscopy, have
responded to medical treatment for neurological diag-
noses.6 Jones described mid-facial segmental pain as
a tension-type pain of neurological origin, pressing or
aching in quality, with a bilateral distribution involving
the nasion, peri-orbital regions, cheeks or paranasal
areas.7 Mid-facial segmental pain involves the frontal,
parietal and occipital regions and is associated with
tension-type headaches.8
Tension-type pain is thought to be due to sensitisa-
tion of second order neurons at the trigeminal
nucleus subcaudalis, which is the facial equivalent of
the dorsal horn of the spinal cord (Figure 1).9 Face,
head and neck afferents converge onto the subnucleus
caudalis. This convergence explains why headache
and neck ache frequently accompany tension-type
facial pain.10,11 Convergence may also explain why
autonomic nasal symptoms frequently accompany
chronic facial pain.
Jones suggested low-dose amitriptyline as an
effective treatment for mid-facial pain.7 Tricyclic
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antidepressants are known to be effective in the
prophylaxis of tension-type headache and are thought
to reduce the sensitivity of second order neurons at
the level of the spinal cord.12
In chronic tension-type headache, as defined by the
International Headache Society classification 2.3,
patients have at least 15 days per month with headache
along with the characteristics detailed in Table I.1 The
criteria for chronic mid-facial pain were extrapolated
from these criteria.
Migraine is a common episodic disorder of the
central nervous system, affecting 10 to 15 per cent of
the population. It is more prevalent in women, with a
female-to-male ratio of 3:1, and peaks at the fourth to
fifth decade of life.13–15 Migraine causes a unilateral
throbbing-type headache with photophobia, phonopho-
bia, nausea and vomiting. The headache sometimes
spreads to the face. In migraine with aura, the pain is
preceded by neurological symptoms such as visual dis-
turbances or numbness. Of 100 patients who referred
themselves for ‘sinus headache’, up to 52 per cent
were classified as having migraine without aura.16
Facial migraine without aura may be easily misdiag-
nosed as ‘sinusitis’ because autonomic nasal symptoms
may be present.17
The International Headache Society defines chronic
migraine as over 15 days per month with headache with
the characteristics described in Table II.
FIG. 1
Schematic diagram of the facial nociceptive pathway. CN= cranial nerve
TABLE I
DIAGNOSTIC CRITERIA FOR CHRONIC TENSION-TYPE
HEADACHE1
A Headache occurring≥15 days per month on average for>3
months, & fulfilling criteria B–D
B Headache lasts for hours or is continuous
C Headache has≥2 of following characteristics:
– Bilateral location
– Pressing or tightening (non-pulsating) quality
– Mild or moderate intensity
– Not aggravated by routine physical activity (e.g. walking or
climbing stairs)
D Both of following:
– No more than 1 of: photophobia, phonophobia or mild nausea
– Neither moderate-to-severe nausea nor vomiting
E Not attributed to another disorder
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Materials and methods
A total of 240 patients who had experienced chronic
mid-facial pain for at least 4 hours daily, for a
minimum of 15 days per month, over a period of at
least 3 months (as per the international classification
of headache disorders1) were eligible for entry into
the study. These patients were prospectively followed
up for 36 months to determine their long-term
outcomes.
The processes of prospective recruitment and follow
up were conducted in accordance with the Consolidated
Standards of Reporting Trials (‘CONSORT’) guide-
lines.18 Patients were selected by applying the
International Headache Society criteria; these were
used to define and differentiate tension-type pain
from facial migraine without aura (Tables I and II)
and from other less common types of facial neuralgia.
Tension-type facial pain and facial migraine become
more difficult to distinguish from each other when
pain frequency increases.19 Some patients with severe
exacerbation of tension-type facial pain experience a
migrainous attack, suggesting an overlap between the
two conditions.20 Migraine with aura was much
easier to distinguish from tension-type pain than
migraine without aura.
The recruitment inclusion and exclusion criteria for
entry into the cohort are listed in Table III. Only
patients aged between 16 and 65 years were recruited.
A standard patient history was taken, as shown in
Table IV.
Basic patient data were collected from patients,
including their state identity number (the unique iden-
tifier number provided by the Maltese government for
every individual), age, sex, address, contact number,
date seen and length of follow up in months. The
main site of facial pain (unilateral, bilateral, alternating,
right or left, frontal, peri-orbital, temporal, occipital or
cheeks), its quality, duration and frequency was
recorded. Exacerbating factors such as light, noise or
exercise were noted, as was a personal history or
family history of migraine.
Pregnant women, and patients with facial trauma or
with pain caused by changes in ambient pressure (such
as flying or diving), were excluded. Patients with tem-
poromandibular dysfunction with clicking, tenderness
of the temporomandibular joint or dental pain related
to thermal sensitivity or percussion of the teeth were
excluded.
Any symptoms that have been implicated in the
diagnosis of rhinosinusitis, such as nasal obstruction,
postnasal drip, rhinorrhoea, hyposmia, cough, fever,
halitosis, toothache, fatigue or ear pressure, were
recorded. Nasal atopy, whether intermittent or persist-
ent, and whether supported by positive skin tests or
not, was also recorded. The presence of rhinitis, or
TABLE III
COHORT INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria
Age 16–65 years
>15 pain days per month for>3 months
Pain affecting mid-face but may also involve head
Normal ENT examination, fundoscopy, cranial nerves & blood
pressure
Normal nasal endoscopy & CT of sinuses & brain
Exclusion criteria
Symptoms of sinusitis (e.g. rhinorrhoea, postnasal drip or
hyposmia)
Sinus surgery within 2 years
Pregnancy
Facial pain associated with barotrauma
Facial trauma
Temporomandibular joint dysfunction & pain of dental origin
Patients on antidepressants, hypnotics, β-blockers, clopidogrel or
aspirin
>One attack migraine per month
Degenerative disease (e.g. multiple sclerosis) or CNS tumours
Alcohol or substance abuse
Medication overuse headache
Sinuses CT shows mucosal thickening>3 mm
CT= computed tomography; CNS= central nervous system
TABLE II
DIAGNOSTIC CRITERIA FOR MIGRAINE WITHOUT
AURA1
A≥ Five attacks fulfilling criteria B–D
B Headache attacks lasting 4–72 hours (untreated or successfully
treated)
C Headache has≥2 of following characteristics:
– Unilateral location
– Pulsating quality
– Moderate or severe pain intensity
– Aggravated by, or causing avoidance of, routine physical
activity (e.g. walking or climbing stairs)
D During headache,≥1 of following:
– Nausea &/or vomiting
– Photophobia & phonophobia
E Not attributed to another disorder
TABLE IV
FACIAL PAIN PATIENTS: STRUCTURED CLINICAL
INTERVIEW AND FOLLOW UP
Length of history
Site: peri-orbital, paranasal, cheeks, frontal, vertex, occipital,
temporal-unilateral, bilateral
Quality: pressing, aching, throbbing
Duration, frequency & intensity
Presence of photophobia, nausea or vomiting
Presence of nasal obstruction, postnasal drip, rhinorrhoea,
hyposmia, cough, fever, halitosis, toothache, ear pressure or
fatigue
History of migraine, or family history of migraine
History of systemic illness (e.g. lung disease)
History of atopy & skin test positivity
Details of past nasal surgery
Cigarette smoke exposure
Analgesic use: type, dose
BMI, education level & occupation or income
Final diagnosis
Signs on nasal endoscopy: normal, pus, polyps, mucosal oedema
CT results: normal, rhinitis, sinusitis, anatomical abnormality
Treatment given
Treatment modified
Outcome or follow up
BMI= body mass index; CT= computed tomography
A M AGIUS, N S JONES, R MUSCAT520
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0022215114000929
Downloaded from https://www.cambridge.org/core. The University of Malta Library, on 17 Aug 2020 at 09:14:10, subject to the Cambridge Core terms of use, available at
other significant respiratory or systemic disease, was
recorded; this is because an association of headaches
with asthma, rhinitis or chronic bronchitis has been
described.21 The presence of atopy, especially if the
patient had positive skin tests, was also recorded.
Exposure to tobacco smoke, whether active or
passive, was recorded. A history of systemic illness
such as hepatic, renal or pulmonary disease was noted.
Any prior surgical treatment was documented, and
only patients whose sinus surgery pre-dated the study
by two years were allowed to participate. Patients
whose facial pain was accompanied by a tension head-
ache were allowed to participate in the study. Patients
with mixed tension-type pain with migraine were
included in the study as long as they did not have
more than one episode of migraine per month, in
accordance with criteria established by previous
studies on tension headache.22–24 Patients with more
frequent migraine were excluded because they have
been shown to have variations in blood serotonin
levels.25 Such variations could affect the outcome of
serotonin estimation carried out as part of this study
on a selected group of patients with mid-facial pain;
however, these results will not be reported in this paper.
Patients with a history of psychiatric illness or those
on any antidepressant, antipsychotic or hypnotic treat-
ment were excluded as such individuals are suspected
to have dysfunctional serotonergic pathways. Indeed,
headaches have been associated with depression.26,27
Individuals with medication overuse headaches were
excluded because they could constitute a particular
group that is difficult to treat and whose medication
may have altered serotonin reuptake activity. Patients
with a history of substance or alcohol abuse were
excluded for the same reasons.
Treatment regimes
As all patients had chronic pain (more than 15 pain
days per month), prophylactic treatment was indicated.
For mid-facial pain, 10 mg amitriptyline at night was
prescribed for eight weeks. A second eight-week
course was prescribed if the patient did not respond
to the initial course of treatment. Patients who relapsed
were continued on this medication for up to one year.
Further relapses were treated with carbamazepine.
Subsequent to this study, we now use pregabalin.
Prophylaxis for patients with facial migraine con-
sisted of 10 mg amitriptyline or 20 mg propranolol
daily for eight weeks. Triptans, being more expensive,
were prescribed for breakthrough episodes or for more
severe pain. Non-steroidal anti-inflammatory drugs
were given as an alternative to triptans to patients not
wishing to have prophylactic treatment. Cost was an
important consideration because patients had to fund
their own treatment.
Treatment success was defined as a greater than 50
per cent reduction in pain frequency, intensity or
both, as laid out in the Cochrane guidelines.28
Follow up
Patients recruited into the cohort were followed up for
three years, from June 2010 to May 2013.
Details of facial pain frequency and severity, medical
treatment, any changes to treatment, and the results of
follow up were recorded. The type and dose of any
medication prescribed, together with outcome and
addition to or change in medication, were noted. If
facial pain recurred after treatment, the elapsed time
between the course of treatment and recurrence was
recorded. Clinical success was defined as a greater
than 50 per cent decrease in pain frequency, pain
intensity or both. Outcome in the cohort follow up at
36 months was broadly classified according to
International Headache Society guidelines as remain-
ing chronic, becoming episodic (1–14 days of pain
per month) or having resolved.
Following the initial interview, all patients were
reviewed after four weeks. Patients were then contacted
for telephone interview at least once per year during
follow up to ascertain the progression of facial pain.
Symptomatic patients could obtain a same-day appoint-
ment at the out-patient clinic if required. Another two
attempts were made to contact those who did not
respond to the telephone call. Failing this, a letter
was sent to their last known address in an attempt to
elicit a response.
Statistics
Statistical analyses were conducted using SPSS
Statistics software version 16.0 (Chicago, Illinois,
USA). Results are presented as mean± standard devi-
ation. Comparisons between patients with mid-facial
tension-type pain and those with facial migraine were
made using a chi-square test. When calculating treat-
ment efficacy, the cut-off point between success and
failure was a greater than 50 per cent improvement in
pain scores. The dichotomous analysis was performed
using the chi-square test. Statistical significance was
set at p< 0.05.
Results
The mean age of 240 patients with chronic facial pain
was 37.7± 12.4 years. Most were women (172, or 72
per cent).
The great majority (156) of these patients were found
to have chronic mid-facial segmental tension-type pain.
Sixty-one patients had facial migraine, of which 16 had
migraine with aura. Eight individuals had a combin-
ation of mid-facial pain and migraine. The remaining
15 had cranial nerve neuralgias, cluster headaches
and temporal arteritis (Table V). Most of the results
relate to the two main patient groups.
The BMI, level of education and occupation of these
patients were compared to national statistics. The
national census of 2005 recorded the Maltese popula-
tion as 404 962.29 Between the ages of 16 and 65
years, 49.5 per cent of the Maltese population were
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women, while 72 per cent of the facial pain cohort were
women.
Body mass index
National statistical data collected by the Health
Department National Survey of 2008 recorded the
mean BMI for the Maltese adult population as
26.5 kg/m2,30 while the mean BMI for 240 patients
with chronic facial pain was 25.4± 4.2 kg/m2.
Education level
Table VI shows the proportion of the population with a
primary, secondary, higher secondary and tertiary level
of education. In general, facial pain patients had a
higher level of education than the general population.
The fact that these patients attended a private clinic
may be relevant to these findings.
Occupation
The national census of 2005 classified occupations into
categories 1 to 10. Housewives, students and pen-
sioners were missing from the national classification
as they were not considered to be gainfully employed.
In this study, these groups were given the code numbers
11, 12 and 13 respectively. Table VII gives the relative
percentages of the different occupations in the chronic
facial pain patient group, together with the national per-
centage for each category.
Patients with chronic facial pain consulting a private
specialist were likely to be better educated and have a
better job than the general population, with a slightly
lower BMI than the national average.
Chronic mid-facial pain
Of the 156 patients with chronic mid-facial tension-
type pain, 111 (71 per cent) were women, with a
mean age of 37± 11.6 years (Table VIII). The 45
men were slightly older, with a mean age of 40± 14
years. The mean age of all mid-facial pain patients
was 37.8± 12.4 years. Dizziness was a common
accompanying symptom to facial pain, occurring in
37 out of 156 (23.7 per cent) patients and usually
resolving within a week of commencing treatment.
Patients with mid-facial pain were treated with an 8-
week course of 10 mg amitriptyline per day and fol-
lowed up for 36 months. If there was no response
after two weeks, the dose was increased to 20 mg, but
this was unusual. In 24 out of 156 patients (15.3 per
cent), pain recurred within 3 months. Even when the
pain was not as severe as it had previously been,
these individuals were offered a second course of
amitriptyline.
Patients who retained their pre-treatment pattern of
pain were classified as having ‘chronic’ pain. In
patients whose pain decreased in frequency and sever-
ity so that they recorded less than one pain day a month,
the pain was considered to be ‘resolved’. Patients with
1–14 pain days per month at 36 months were labelled
as having ‘episodic’ pain.
Facial pain resolved in almost half of the mid-facial
pain patients (45.5 per cent), while in a third it changed
to an episodic pattern (37.2 per cent) with infrequent
bouts of pain (Table IX). In 14 patients (9 per cent),
chronic pain was retained, that is, they had more than
15 pain days per month. The remaining 8.3 per cent
were lost to follow up.
For those patients in the episodic and chronic groups
whose pain returned, it did so after 10.5± 10 months
following their course of amitriptyline.
TABLE VI
EDUCATION LEVEL IN GENERALMALTESE AND STUDY
POPULATIONS
Population Primary Secondary Higher
secondary
Tertiary
General
Maltese (%)
28.8 45.2 13.8 12.2
Current study∗
(%)
– 37.2 29.9 32.9
∗n= 240
TABLE VII
OCCUPATION TYPE IN GENERAL MALTESE AND STUDY
POPULATIONS
Type Population (%)
General
Maltese
Study
Armed forces 1 0
Legislator, senior official or manager 9 8
Professional 11.7 14.3
Technician or associate professional 12.5 8.8
Clerical 14.8 20.6
Service worker, shop & sales worker 16.3 10.5
Skilled agricultural or fishery worker 1.5 0
Crafts or trade worker 13.6 2.9
Plant or machine operator or
assembler
9.1 6.7
Elementary occupations 10.5 4.7
Housewife – 18
Student – 3.4
Pensioner – 2.1
TABLE V
CHRONIC FACIAL PAIN CAUSES
Diagnosis Patients
n %
Chronic MFP 156 65
Facial migraine 61 25.5
Chronic MFP & migraine 8 3.3
CN V neuralgia 4 1.7
Cluster headache 3 1.3
CN IX neuralgia 2 0.8
MFP & CN V neuralgia 2 0.8
Temporal arteritis 1 0.4
Glaucoma 1 0.4
MFP & cervical spondylosis 1 0.4
Combined CN IX & V neuralgia 1 0.4
MFP=mid-facial pain; CN= cranial nerve
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Facial migraine
A total of 61 patients had facial migraine: 41 (67.2 per
cent) were women (mean age 35± 10.9 years) and 20
were men (mean age 38.5± 10.9 years) (Table VIII).
The mean age of all facial migraine patients was
36.1± 10.9 years. Dizziness was described in only
four (6.5 per cent) facial migraine patients.
Patients were treated prophylactically with 10 mg
amitriptyline daily for eight weeks (n= 16) or propran-
olol 20 mg daily for eight weeks (n= 21). One patient
was treated with both. Patients who did not accept
prophylactic treatment received triptans (sumatriptan
or zolmitriptan, n= 8) or non-steroidal anti-inflamma-
tory drugs (n= 13) on an ‘as required’ basis. One took
paracetamol with codeine and one did not receive any
treatment. The choice of treatment was influenced by
patient preference and cost.
Patients were followed up for 36 months. On evalu-
ation at 36 months, the largest proportion of facial
migraine patients (41 per cent) had unchanged
chronic symptoms. In 23 per cent, their pain had
‘resolved’ to less than one episode per month. In one-
third, the pain frequency was reduced to ‘episodic’,
i.e. occurring between 1 and 14 days per month
(Table IX). Overall, in patients whose facial migraine
did not resolve (‘chronic’ and ‘episodic’ groups
together), the original pain pattern took a mean of
8.7± 10 months to return after treatment. In 18 patients
(30 per cent), pain returned within 3 months of stop-
ping treatment.
In the subgroup of patients receiving prophylactic
propranolol (n= 21), the previous pain pattern returned
after 13.3± 12.3 months; in those receiving prophylac-
tic amitriptyline (n= 16), pain returned after 18.4±
16.1 months; and in patients receiving triptans (n= 8),
the previous pain pattern returned after 19.3± 17.9
months. The shortest interval before return to the
previous pain pattern was seen in patients receiving
non-steroidal anti-inflammatory drugs ‘as required’
(n= 13): their pain returned after 9.7± 13.3 months.
Mid-facial pain versus facial migraine
A comparison of outcomes revealed that patients with
mid-facial pain and facial migraine had similar
dropout rates on follow up (chi-square test, p= 0.69
(not significant)), and similar rates of progression
from chronic to episodic pain (chi-square test, p=
0.27 (not significant)). However, mid-facial pain
patients were much more likely to experience reso-
lution of their pain compared to patients with migraine
(p= 0.05), and facial migraine was significantly more
likely to remain chronic (p= 0.00001).
The most common sites of pain described by patients
with mid-facial pain were the nasion and frontal
regions; most had a combination of sites, with 384
sites described by 156 patients. In facial migraine,
141 sites were described by 61 patients, with the
peri-orbital and frontal regions being most commonly
involved (Table X). In mid-facial pain, the pain was
typically bilateral; in migraine, it was bilateral in half
of patients (26, or 48 per cent), and unilateral or alter-
nating in the other half.
In mid-facial pain, the pain was characteristically
pressing in 122 patients (78 per cent) and aching in 30
patients (19 per cent). In facial migraine, the pain was
described as throbbing in 34 patients (56 per cent), as
pressing in 17 (28 per cent), and as aching, stabbing,
boring, pinching or sharp in the rest. Thus, the descrip-
tion of pain in mid-facial pain was more uniform.
Photophobia and nausea were much more common
in facial migraine (Table XI). Most facial migraine
patients had never been properly diagnosed and had a
low awareness of this condition. As a consequence,
they typically denied a history of migraine and attribu-
ted their previous symptoms to sinusitis. However,
when asked about migraine in their families, the rates
turned out to be high.
The incidence of rhinitis, and rates of positive skin
tests, exposure to cigarette smoke or systemic illness
such as asthma were similar in the mid-facial pain
and facial migraine groups (Table XII).
Mid-facial pain and facial migraine
In 8 patients with a combination of mid-facial pain and
migraine, the pain pattern reappeared after a mean of
12.6± 4.5 months after treatment with amitriptyline.
TABLE VIII
DEMOGRAPHIC DATA FOR MID-FACIAL PAIN AND FACIAL MIGRAINE PATIENTS
Group Patients (n (%)) Age (mean± SD, years)
Men Women Men Women
MFP∗ 45 (29) 111 (71) 40± 14.0 37± 11.6
Facial migraine† 20 (33) 41 (67) 38.5± 10.9 35± 10.9
∗n= 156; †n= 61. SD= standard deviation; MFP=mid-facial pain
TABLE IX
OUTCOME INMID-FACIAL PAIN AND FACIALMIGRAINE
PATIENTS∗
Group Resolved Episodic Chronic Lost
MFP† 71 (45.5) 58 (37.2) 14 (9) 13 (8.3)
Facial migraine‡ 14 (23) 15 (24.5) 25 (41) 7 (11.5)
Data represent patient numbers and percentages. ∗At 36-month
follow up. †n= 156; ‡n= 61. MFP=mid-facial pain
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Neuralgia and cluster headache
Most patients with trigeminal or glossopharyngeal
neuralgia responded well to carbamazepine, while
those with cluster headaches responded to triptans or
prophylactic low-dose propranolol.
Discussion
This cohort represents a sample of patients who either
self-referred or were referred by their general practi-
tioner to a community-based otolaryngologist, and
may therefore not be representative of patients in the
whole population with chronic facial pain. It is also
likely that a broader spectrum of pain types would be
encountered in an otolaryngological practice than in a
tertiary referral neurological centre. The age and
gender distribution in patients with facial pain in
Malta was very similar to that in a group of 409 patients
with facial pain presenting to a rhinology clinic in the
UK, where the mean age was 37.6 years and 68.6 per
cent were female.31
The patients in this cohort had a similar mean BMI
to that of the general population, but were better edu-
cated. The fact that the patients attended a private prac-
tice may be relevant to these findings. In previous
studies, patients with chronic tension headache were
low academic achievers32 and had lower incomes33
than the general population. In men, tension-type head-
aches were associated with sedentary occupations.34
Patient dropout rates varied between 8 and 11 per
cent. Most tension-type pain was described as of
mild-to-moderate intensity; therefore, not all patients
may have thought it worth the time and effort to
attend follow up. Most individuals were already
taking analgesics on an ‘as required’ basis and there
was some resistance to changing to prophylactic
treatment. Therefore, patient education was important
to explain the aetiology of their condition. It was
encouraging that in patients with mid-facial pain,
pain frequency or severity significantly dropped
within two weeks of starting low-dose amitriptyline.35
A 10-year follow-up study of 62 Danish patients
with chronic tension-type headache showed that 45
per cent went into remission. A reduction in headache
frequency led to the development of an episodic
pattern from a chronic pattern of headaches.36
The same findings were reported in another Danish
study of 740 individuals with headache followed up
for 2 years.37 Similar data were also recorded in the
USA.38 However, patients with coexisting chronic
tension-type headache and migraine were more likely
to continue having frequent headaches. Similar obser-
vations for facial pain were recorded in this study
(Table IX). Clinical improvement (‘resolved’ and ‘epi-
sodic’ outcomes taken together) was much higher in
mid-facial pain patients (82.7 per cent) than in facial
migraine patients (51 per cent).
The treatment of mid-facial pain patients was
uniform and the outcome more favourable. Facial
migraine patients treated with non-steroidal anti-
inflammatory drugs ‘as required’ were quick to return
to their previous pain pattern, while prophylactic low-
dose amitriptyline or triptans seemed to break the
pain cycle and give longer-lasting relief.
Because time to recurrence of the original pain
pattern was, in general, similar in both mid-facial
pain and facial migraine patients, a common underlying
cause of these conditions is hypothesised. Medication
may simply reduce the sensitivity of the nociceptive
pathway for a variable period of time, probably at the
TABLE X
SITES OF CHRONIC FACIAL PAIN∗
Group Frontal Nasion Peri-orbital Cheeks Temporal Occipital
MFP† 109 (70) 97 (62) 72 (46) 49 (31) 27 (17) 30 (19)
Facial migraine‡ 32 (52) 22 (36) 31 (51) 17 (28) 27 (44) 12 (20)
Data represent patient numbers and percentages. ∗Patients generally had more than one site involved at the same time. †n= 156; ‡n= 61.
MFP=mid-facial pain
TABLE XI
ADDITIONAL MEDICAL HISTORY AND SYMPTOMS FOR
MID-FACIAL PAIN AND FACIAL MIGRAINE PATIENTS
Group History of
migraine
Photophobia Nausea &/or
vomiting
Self Family
MFP∗ 35 (22) 39 (25) 45 (29) 42 (27)
Facial
migraine†
9 (15) 37 (61) 45 (74) 31 (51)
Data represent patient numbers and percentages. ∗n= 156; †n=
61. MFP=mid-facial pain
TABLE XII
RHINITIS, POSITIVE SKIN TESTS, SMOKE EXPOSURE
AND SYSTEMIC ILLNESS IN MID-FACIAL PAIN AND
FACIAL MIGRAINE PATIENTS
Group Rhinitis Positive skin
test
Smoke
exp
Syst
illness∗
MFP† 35 (22) 8 (5) 22 (14) 6 (4)
Facial
migraine‡
10 (16) 1 (2) 10 (16) 1 (2)
Data represent patient numbers and percentages. ∗For example,
asthma. †n= 156; ‡n= 61. Exp= exposure; syst= systemic;
MFP=mid-facial pain
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level of the synaptic relay in the trigeminal subnucleus
caudalis.
• In a cohort of chronic facial pain patients, 72
per cent were women in their fourth decade
• Patients had a slightly lower mean body mass
index, and better educations and jobs, than
the general population
• Commonest causes of pain were tension-type
mid-facial pain and facial migraine
• Patients with tension-type mid-facial pain
responded to low-dose amitriptyline
• Patients with facial migraine responded to
low-dose amitriptyline and triptans
The pain resolved in nearly half of the individuals with
mid-facial pain, and in a third it became episodic. We
do not know whether the medication altered the
natural course of the condition as no long-term study
of untreated patients with this condition has been per-
formed. However, these findings are similar to those
obtained for tension-type headache patients.39
Photophobia has been reported in 49–95 per cent of
patients with migraine.40,41 In this series, the incidence
was 74 per cent in facial migraine patients, which is
consistent with the other studies (Table XI).
Nausea has been reported as present in 90 per cent
of patients with migraine, with vomiting present in 50
per cent.40,41 The rates of these symptoms in facial
migraine patients in this study were similar (Table XI).
The rates of rhinitis, positive skin test results, cigar-
ette smoke exposure or systemic illness such as asthma
were similar in the mid-facial pain and facial migraine
groups, and did not differ from those in the general
Maltese population.42 This contrasts with findings
from a Norwegian study, which showed an association
of asthma, rhinitis and chronic bronchitis with migrain-
ous and non-migrainous headaches.21
Education is important to encourage patients to keep
analgesic doses as low as possible. This will help to
prevent the development of medication overuse head-
aches, especially those resulting from migraine medica-
tion overuse.43
During the three years follow up, two of the patients
became pregnant; their facial pain significantly
improved during pregnancy. In one female patient
with facial migraine, thyroid nodules were incidentally
discovered and she was eventually diagnosed with
medullary carcinoma of the thyroid.
Conclusion
In this cohort of patients with chronic facial pain, 72
per cent were women in their fourth decade of life.
As a group, the cohort had a slightly lower than
average BMI, better educational attainment and better
jobs compared with the general population.
The commonest causes of pain were tension-type
mid-facial pain and facial migraine. Patients in
the first group frequently responded to an 8-week
course of low-dose amitriptyline, with nearly half of
the patients being pain free at 36 months and one-
third suffering less severe and less frequent episodes
of pain. For patients with facial migraine, the most
effective long-term treatment was low-dose amitriptyl-
ine and triptans.
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